Hasil Pencarian  ::  Simpan CSV :: Kembali

"Menurut Peraturan Pemerintah Republik Indonesia Nomor 51 Tahun 2009, pekerjaan kefarmasian adalah pembuatan termasuk pengendalian mutu Sediaan Farmasi, pengamanan, pengadaan, penyimpanan dan pendistribusian atau penyaluran obat, pengelolaan obat, pelayanan obat atas resep dokter, pelayanan informasi obat, serta pengembangan obat, bahan obat dan obat tradisional. Pekerjaan kefarmasian tersebut dilakukan oleh seorang apoteker. Gelar apoteker didapat dari pendidikan profesi yang ditempuh setelah sarjana farmasi. Seorang apoteker dituntut untuk memiliki kemampuan akademik dan kemampuan profesi dalam mengaplikasikan Pekerjaan Kefarmasian. Oleh karena itu, calon apoteker harus dibekali ilmu-ilmu secara teori maupun praktik. Keilmuan secara praktik didapatkan melalui program praktik kerja profesi apoteker PKPA. Program PKPA dilaksanakan Apotek Roxy Pitara, Puskesmas Kecamatan Jagakarsa dan PT. Ethica Industri Farmasi dari bulan Januari hingga bulan April 2022. Melalui program PKPA ini, calon apoteker diharapkan dapat menambah keilmuan dan wawasan terkait pekerjaan kefarmasian sehingga nantinya menjadi bekal bagi calon apoteker sendiri ketika memasuki dunia kerja.

---

According to Government Regulation of the Republic of Indonesia Number 51 of 2009, pharmaceutical work is the manufacturing including quality control of Pharmaceutical Preparations, security, procurement, storage, and distribution or distribution of drugs, drug management, and drug services based on doctor's prescriptions, drug information services, as well as drug development, drug ingredients. and traditional medicine. Pharmacy work is carried out by a pharmacist. A pharmacist's degree is obtained from professional education taken after a pharmacy degree. A pharmacist is required to have academic ability and professional ability in applying to Pharmaceutical Work. Therefore, prospective pharmacists must be equipped with theoretical and practical knowledge. Practical knowledge is obtained through the PKPA pharmacist professional practice program. The PKPA program was carried out by Roxy Pitara Pharmacy, Jagakarsa Community Health Center, and PT. Pharmaceutical Industry Ethica from January to April 2022. Through this PKPA program, prospective pharmacists are expected to be able to add knowledge and insight related to pharmaceutical work so that they will later become provisions for prospective pharmacists themselves when entering the world of work."

"Inhibitor Dipeptidil Peptidase-4 (DPP-4) bekerja dengan menghambat Dipeptidil peptidase-4 (DPP-4). Golongan obat tersebut menjadi terapi yang menjanjikan untuk pasien Diabetes Melitus Tipe 2 (DMT2) karena dapat meningkatkan level hormon inkretin hingga 50% dalam plasma darah serta tidak memiliki efek samping penambahan berat badan dan hipoglikemia. Sayangnya, salah satu obat golongan inhibitor DPP-4, yaitu Vildagliptin, memiliki beberapa efek samping yang cukup serius karena selektivitasnya yang buruk dalam menghambat DPP-4. Selektivitas Vildagliptin dapat ditingkatkan dengan mengganti gugus adamantil pada Vildagliptin dengan struktur yang lebih besar. Penelitian ini bertujuan untuk mensintesis senyawa 2-(Azidometil)-6-nitro-4(3H)-kuinazolinon sebagai senyawa antara tahap 1 pada sintesis senyawa hibrid 1-(2-{[(6-nitro-4-oxo-3,4-dihidrokuinazolin-2-il)metil]amino}asetil)pirolidin-2-karbonitril. Sintesis dilakukan dengan mereaksikan 2-(Bromometil)-6-nitro-4(3H)-kuinazolinon dengan natrium azida menggunakan metode Microwave Assisted Organic Synthesis (MAOS). Produk yang dihasilkan dimurnikan dengan metode ekstraksi padat-cair, kemudian diuji kemurniannya dengan KLT dan jarak lebur. Karakterisasi senyawa hasil sintesis menggunakan spektrofotometri FT-IR dan Spektroskopi 1H-NMR mengindikasikan bahwa senyawa 2-(Azidometil)-6-nitro-4(3H)-kuinazolinon telah terbentuk, namun masih belum murni. Nilai rendemen yang senyawa 2-(Azidometil)-6-nitro-4(3H)-kuinazolinon yang didapatkan sebesar 58,6%.

---

Dipeptidyl Peptidase-4 (DPP-4) inhibitors have activity in inhibiting Dipeptidyl peptidase-4 (DPP-4). This class of drugs is a promising therapy for Type 2 Diabetes Mellitus (DMT2) patients because it can increase incretin hormone levels up to 50% in blood plasma and has no side effects of weight gain and hypoglycemia. Unfortunately, one of the DPP-4 inhibitors, namely Vildagliptin, has some serious side effects due to its poor selectivity in inhibiting the DPP-4. The selectivity of Vildagliptin can be increased by replacing the adamantyl group on Vildagliptin with a larger structure. This study aims to synthesize the compound 2-(Azidomethyl)-6-nitro-4(3H)-quinazolinone as an intermediate in step 1 in the synthesis of the hybrid compound 1-(2-{[(6-nitro-4-oxo-3,4 -dihydroquinazoline-2-yl)methyl]amino}acetyl)pyrrolidin-2-carbonitrile. The synthesis was carried out by reacting 2-(Bromomethyl)-6-nitro-4(3H)-quinazolinone with sodium azide using the Microwave Assisted Organic Synthesis (MAOS) method. The resulting product was purified by solid-liquid extraction method, then tested for purity by TLC and melting point. Characterization of the synthesized compound using FT-IR spectrophotometry and 1H-NMR spectroscopy indicated that the compound 2-(Azidomethyl)-6-nitro-4(3H)-quinazolinone had been formed, but was still not pure. The yield value of the compound 2-(Azidomethyl)-6-nitro-4(3H)-quinazolinone obtained was 58.6%"